The Antibody Based Therapy Revolution

Cancer Research is big business and many people who are involved in this practice take their jobs mighty seriously. Dealing with cancer can be life or death and these advanced thinkers are just as powerful as the treatments they help to create. Change is good no matter the situation and cancer research is no exception. Thanks to so much advanced technology currently available on he market, cancer could become a relevant and a thing of the past. This is the 21st Century no matter which way you view it and if the old ways of doing something isn’t working anymore, change is sure to happen. Dr. Clay Siegall knows this perfectly and his Biotechnology Company Seattle Genetics is taking big steps to make this a reality. Dr. Siegall has been in the industry for many years and has worked with some of the most prestigious names such as The National Institute of health, Bristol Myers Squibb, and The National Cancer Institute. He has (BS) in Zoology from the University of Maryland and a Ph.D from George Washington University.

Seattle Genetics has created some of the biggest industry buzz as of late thanks to it’s advanced technology in cancer research. The company focuses on the development and commercialization of antibody based therapies. This therapies are far more advanced than the drugs before them and works in a variety of ways to fight cancer. These antibody drug conjugates deliver cell killing agents directly into cancerous cells which wipes them out much more effectively than Chemotherapy. Besides that these drugs spare any and all non-targeted cells (which are the good cells) and leave the patients with no ill side effects.

Antibody Based Therapy is the way to go and Seattle Genetics has layed the blueprint to success. Under the watchful eye of Dr. Clay Siegall, these treatments will become far more advanced in years to come.